Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 10 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer – first line Atezolizumab (Tecentriq; MPDL3280A) Urothelial cancer Urological Cancer 2020 View  |  Download
Enfortumab vedotin for locally advanced or metastatic urothelial cancer Enfortumab vedotin (ASG-22ME; Padcev) Urothelial cancer Urological Cancer 2020 View  |  Download
Enfortumab vedotin with pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2022 View  |  Download
Erdafitinib capsules for metastatic or surgically unresectable urothelial cancer with FGFR gene aberrations – second line therapy Erdafitinib (JNJ-42756493; BALVERSA) Urothelial cancer Urological Cancer 2017 View  |  Download
Nivolumab for high risk invasive urothelial carcinoma - adjuvant Nivolumab (Opdivo; BMS-936558; ONO-4538) Urothelial cancer Urological Cancer 2019 View  |  Download
Nivolumab in combination with chemotherapy for previously untreated unresectable or metastatic urothelial cancer Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538) Urothelial cancer Urological Cancer 2022 View  |  Download
Nivolumab in combination with ipilimumab for previously untreated unresectable or metastatic urothelial cancer – first-line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Urothelial cancer Urological Cancer 2020 View  |  Download
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2024 View  |  Download
Pembrolizumab in addition to chemotherapy for advanced or metastatic urothelial cancer - first line Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2018 View  |  Download
Sacituzumab govitecan for urothelial cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Urothelial cancer Urological Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications